Advertisement

Autolus Therapeutics plc AUTL

Set alert

Price alert · AUTL

All alert types
1.52 USD -0.06 -3.80%

At close · Oct 30

1.51 -0.01 -0.62%

After hours · Oct 30, 6:37 PM ET

Bid
1.51 × 2
Ask
1.52 × 2
1.48 Day range 1.59
1.21 52-week range 2.54
YTD
-23.62%
1 year
+0.66%
Open
1.58
Prev close
1.58
Mkt cap
404.57M
Vol
1.68M
Avg vol
2.27M
EPS
-1.06
P/E
0.00
Div yield
0.00%
More statistics
Low
1.48
High
1.59
Forward P/E
-3.08
Beta
0.00
Short ratio
2.48
Inst. own
77.47%
Dividend
0.00
Ex-div date
Earnings
Aug 8, 2024
50-d avg
3.39
200-d avg
4.08
1y target
10.45

MAX chart

Chart tools
Interval

Events in this range
  • Mar 14, 2024Earnings: -0.44; estimate -0.26; surprise -69.23%
  • May 17, 2024Earnings: -0.24; estimate -0.1; surprise -140%
  • May 17, 2024Earnings: —; estimate -0.1; surprise —%
  • Aug 8, 2024Earnings: -0.22; estimate -0.19; surprise -15.79%
  • Aug 8, 2024Earnings: —; estimate -0.19; surprise —%
  • Nov 12, 2024Rating: Needham · Buy → Buy
  • Nov 12, 2024Earnings: -0.31; estimate -0.21; surprise -47.62%
  • Nov 13, 2024Rating: Needham · Buy → Buy
  • Nov 15, 2024Rating: Redburn Atlantic · Neutral → Buy
  • Nov 18, 2024Rating: Goldman Sachs · Neutral → Buy
  • Dec 5, 2024Rating: Needham · Buy → Buy
  • Dec 9, 2024Rating: Needham · Buy → Buy
Signals (163)
NameDateAgo
SMA: BearishOct 12, 20262 weeks ago
MACD: Sell SignalSep 28, 20261 month ago
SMA: BearishSep 7, 20261 month ago
RSI: OverboughtAug 17, 20262 months ago
SMA: BullishAug 3, 20262 months ago
SMA: BullishAug 3, 20262 months ago
MACD: Buy SignalAug 3, 20262 months ago
MACD: Sell SignalJul 20, 20263 months ago
SMA: BearishJul 13, 20263 months ago
SMA: BearishJun 29, 20264 months ago
SMA: BullishJun 22, 20264 months ago
SMA: BullishJun 22, 20264 months ago
SMA: BearishJun 15, 20264 months ago
SMA: BearishJun 1, 20265 months ago
SMA: BullishMay 4, 20266 months ago
SMA: BullishApr 27, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BullishApr 6, 20266 months ago
MACD: Buy SignalApr 6, 20266 months ago
MACD: Sell SignalMar 23, 20267 months ago
SMA: BearishMar 2, 20268 months ago
SMA: BearishMar 2, 20268 months ago
SMA: BullishFeb 16, 20268 months ago
SMA: BullishFeb 16, 20268 months ago
SMA: BearishJan 12, 20269 months ago
SMA: BearishJan 12, 20269 months ago
SMA: BullishDec 29, 202510 months ago
SMA: BullishDec 1, 202511 months ago
MACD: Buy SignalDec 1, 202511 months ago
SMA: BearishNov 3, 202512 months ago
SMA: BullishOct 27, 20251 year ago
SMA: BearishOct 20, 20251 year ago
SMA: BullishOct 6, 20251 year ago
MACD: Sell SignalAug 25, 20251 year ago
SMA: BearishAug 11, 20251 year ago
SMA: BullishJun 2, 20251 year ago
SMA: BullishMay 19, 20251 year ago
MACD: Buy SignalApr 28, 20251 year ago
MACD: Sell SignalNov 11, 20241 year ago
SMA: BearishOct 28, 20242 years ago
SMA: BearishOct 28, 20242 years ago
SMA: BullishOct 14, 20242 years ago
SMA: BullishSep 30, 20242 years ago
MACD: Buy SignalSep 30, 20242 years ago
MACD: Sell SignalSep 23, 20242 years ago
MACD: Buy SignalSep 9, 20242 years ago
SMA: BearishAug 26, 20242 years ago
SMA: BullishAug 19, 20242 years ago
SMA: BearishAug 5, 20242 years ago
MACD: Sell SignalAug 5, 20242 years ago
MACD: Buy SignalJul 29, 20242 years ago
SMA: BullishJul 8, 20242 years ago
SMA: BearishJun 17, 20242 years ago
SMA: BullishJun 10, 20242 years ago
SMA: BearishApr 15, 20242 years ago
SMA: BearishApr 1, 20242 years ago
SMA: BullishMar 18, 20242 years ago
MACD: Sell SignalMar 4, 20242 years ago
SMA: BearishFeb 19, 20242 years ago
RSI: OverboughtDec 18, 20232 years ago
SMA: BullishOct 30, 20233 years ago
MACD: Buy SignalOct 30, 20233 years ago
SMA: BullishOct 16, 20233 years ago
SMA: BearishSep 18, 20233 years ago
MACD: Sell SignalSep 18, 20233 years ago
SMA: BearishSep 11, 20233 years ago
SMA: BullishJul 17, 20233 years ago
SMA: BearishJun 26, 20233 years ago
SMA: BullishMay 15, 20233 years ago
SMA: BullishMay 1, 20233 years ago
SMA: BearishMar 20, 20233 years ago
SMA: BullishMar 13, 20233 years ago
SMA: BearishFeb 20, 20233 years ago
SMA: BullishJan 30, 20233 years ago
MACD: Buy SignalJan 30, 20233 years ago
SMA: BearishDec 5, 20223 years ago
SMA: BearishDec 5, 20223 years ago
MACD: Sell SignalDec 5, 20223 years ago
SMA: BullishNov 28, 20223 years ago
SMA: BullishNov 28, 20223 years ago
MACD: Buy SignalNov 28, 20223 years ago
MACD: Sell SignalNov 14, 20223 years ago
SMA: BearishOct 31, 20224 years ago
SMA: BearishOct 31, 20224 years ago
SMA: BullishOct 3, 20224 years ago
SMA: BullishOct 3, 20224 years ago
MACD: Buy SignalOct 3, 20224 years ago
MACD: Sell SignalSep 26, 20224 years ago
SMA: BearishSep 5, 20224 years ago
SMA: BearishAug 29, 20224 years ago
SMA: BullishAug 22, 20224 years ago
SMA: BearishAug 15, 20224 years ago
SMA: BullishAug 1, 20224 years ago
SMA: BullishJun 27, 20224 years ago
MACD: Buy SignalJun 27, 20224 years ago
MACD: Sell SignalApr 25, 20224 years ago
SMA: BearishApr 11, 20224 years ago
MACD: Buy SignalMar 21, 20224 years ago
SMA: BullishMar 14, 20224 years ago
MACD: Sell SignalDec 20, 20214 years ago
SMA: BearishDec 13, 20214 years ago
SMA: BearishDec 13, 20214 years ago
SMA: BullishDec 6, 20214 years ago
SMA: BullishDec 6, 20214 years ago
SMA: BearishNov 29, 20214 years ago
SMA: BearishNov 15, 20214 years ago
SMA: BullishNov 8, 20214 years ago
SMA: BullishNov 8, 20214 years ago
MACD: Buy SignalNov 8, 20214 years ago
MACD: Sell SignalOct 25, 20215 years ago
SMA: BearishOct 4, 20215 years ago
SMA: BearishOct 4, 20215 years ago
SMA: BullishSep 27, 20215 years ago
SMA: BearishSep 20, 20215 years ago
SMA: BullishAug 23, 20215 years ago
SMA: BullishAug 23, 20215 years ago
SMA: BearishJul 12, 20215 years ago
SMA: BearishJun 21, 20215 years ago
SMA: BullishJun 7, 20215 years ago
SMA: BullishMay 10, 20215 years ago
MACD: Buy SignalMay 3, 20215 years ago
SMA: BearishOct 12, 20206 years ago
SMA: BullishOct 5, 20206 years ago
SMA: BearishSep 28, 20206 years ago
MACD: Sell SignalSep 7, 20206 years ago
SMA: BearishAug 31, 20206 years ago
SMA: BullishAug 3, 20206 years ago
SMA: BearishJul 20, 20206 years ago
SMA: BullishMay 11, 20206 years ago
MACD: Buy SignalApr 13, 20206 years ago
SMA: BullishApr 6, 20206 years ago
RSI: OversoldMar 9, 20206 years ago
MACD: Sell SignalFeb 24, 20206 years ago
MACD: Buy SignalFeb 10, 20206 years ago
MACD: Sell SignalFeb 3, 20206 years ago
SMA: BearishDec 30, 20196 years ago
SMA: BearishDec 30, 20196 years ago
SMA: BullishDec 23, 20196 years ago
SMA: BullishDec 23, 20196 years ago
SMA: BearishDec 9, 20196 years ago
SMA: BearishDec 9, 20196 years ago
SMA: BullishNov 25, 20196 years ago
SMA: BullishNov 18, 20196 years ago
SMA: BearishNov 4, 20196 years ago
SMA: BullishOct 7, 20197 years ago
SMA: BearishSep 23, 20197 years ago
MACD: Buy SignalSep 9, 20197 years ago
SMA: BullishSep 2, 20197 years ago
RSI: OversoldAug 26, 20197 years ago
RSI: OversoldAug 12, 20197 years ago
SMA: BearishApr 8, 20197 years ago
SMA: BearishApr 1, 20197 years ago
SMA: BullishMar 25, 20197 years ago
SMA: BullishMar 25, 20197 years ago
SMA: BearishJan 21, 20197 years ago
SMA: BearishDec 10, 20187 years ago
RSI: OverboughtNov 5, 20187 years ago
SMA: BullishOct 29, 20188 years ago
SMA: BearishOct 22, 20188 years ago
SMA: BullishOct 15, 20188 years ago
SMA: BearishOct 1, 20188 years ago

Key statistics

Market cap
598.77M
Enterprise value
253.44M
Trailing P/E
0.00
Forward P/E
-3.08
PEG ratio
0.00
Price / sales
59.34
Price / book
1.25
EPS (TTM)
-1.22
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
10.09M
Revenue growth
0.00%
Free cash flow
-171.18M
Total cash
657.07M
Total debt
301.17M
Return on equity
-82.20%
Shares outstanding
266.12M
Short % of float
3.19%
50-day average
3.39
200-day average
4.08

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 10.45 +587.5% upside
Target (low)
7.60
Target (mean)
10.45
Target (high)
13.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy8
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 8, 2024

Expected Aug 8, 2024. Consensus EPS estimate -0.22411.

Earnings history

Financials — quick view

All financials
AUTL Revenue — quarterly 45.69M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AUTL Net income — quarterly -39.11M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AUTL EPS — quarterly -0.15
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

AUTL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.21-0.31-0.10-47.62%
Aug 8, 2024Jun 1, 2024-0.19-0.22-0.03-15.79%
Aug 8, 2024Jun 1, 2024-0.19———
May 17, 2024Mar 1, 2024-0.10-0.24-0.14-140.00%
May 17, 2024Mar 1, 2024-0.10———
Mar 14, 2024Dec 1, 2023-0.26-0.44-0.18-69.23%

Upgrades / downgrades

AUTL analyst upgrades and downgrades
DateFirmActionFromTo
Dec 9, 2024NeedhamreitBuyBuy
Dec 5, 2024NeedhamreitBuyBuy
Nov 18, 2024Goldman SachsupNeutralBuy
Nov 15, 2024Redburn AtlanticupNeutralBuy
Nov 13, 2024NeedhamreitBuyBuy
Nov 12, 2024NeedhammainBuyBuy

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
Website
autolus.com

News

Your note

Sign in to keep a note on AUTL — it syncs with the Stock Master app.

Institution ownership

AUTL institution ownership
Holder% heldSharesValueReported
Wellington Management Group, LLP9.10%24,220,22654.50MSep 29, 2024
Blackstone Inc7.70%20,485,61146.09MSep 29, 2024
Syncona Portfolio Ltd6.97%18,554,62441.75MSep 29, 2024
FMR, LLC6.68%17,773,87339.99MSep 29, 2024
Deep Track Capital, Lp5.74%15,272,17234.36MSep 29, 2024
Avoro Capital Advisors LLC4.64%12,345,67827.78MSep 29, 2024

Fund ownership

AUTL fund ownership
Holder% heldSharesValueReported
Vanguard Specialized-Health Care Fund7.10%18,895,10742.51MJul 30, 2024
Fidelity Small Cap Growth Fund0.97%2,571,3715.79MAug 30, 2024
Fidelity Series Small Cap Opportunities Fund0.94%2,513,4755.66MAug 30, 2024
Price (T.Rowe) New Horizons Fund0.85%2,268,4555.10MSep 29, 2024
Fidelity Advisor Biotechnology Fund0.73%1,940,3464.37MOct 30, 2024
Fidelity Stock Selector Small Cap Fund0.64%1,706,6793.84MAug 30, 2024
Advertisement